We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Integrated Chip System Developed As Complete Laboratory

By LabMedica International staff writers
Posted on 23 Jan 2011
A device, based on chip technology, has been developed that will enable the diagnosis of eight or more different diseases on blood or cell samples. More...


The integrated system based on micro-technology and biotechnology, will enable a number of conditions to be diagnosed automatically in the doctor's own office. The chip looks like a credit card and contains a complete laboratory.

The chip is engraved with a number of very narrow channels that contain chemicals and enzymes in the correct proportions for each individual analysis. When the patient's sample has been drawn into the channels, these reagents are mixed. The card is then put into a machine than can read the biomarkers, such as DNA or enzymes, to produce a diagnosis. The project to develop the chip is being coordinated by SINTEF (Trondheim, Norway), the largest independent research organization in Scandinavia.

Scientists at SINTEF's micro and nanotechnology laboratory have developed a number of techniques for interpreting the results when the biomarkers have been found. For example, they can read them off in a spectrophotometer, an optical instrument in which the ribonucleic acid (RNA) molecules in different markers emit specific fluorescent signals. The project has used cells taken to diagnose cervical cancer as a case study, but in principle, the chip can check out a number of different diseases caused by bacteria or viruses, as well as various types of cancer.

NorChip, (Klokkarstua, Norway), the company that had the original idea, has just started a new two-year EU project that aims to industrialize the diagnostic chip to the mass-production stage while the company will also evaluate market potential and industrial partners. Frank Karlsen, Ph.D., the Chief Scientist at NorChip, said, "The ways in which the chip can be used can be extended to enable patients themselves to take samples at home", and he expects that such special sampling systems will be ready for testing within a few years. The venture is part of the European Commission's (Brussels, Belgium) project ‘Microactive' develops 'in-office' health test system."

Related Links:

SINTEF
NorChip
European Commission



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.